Novartis AG (NVS) Given Buy Rating at JPMorgan Chase & Co.
Novartis AG (NYSE:NVS)‘s stock had its “buy” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Friday.
NVS has been the subject of a number of other research reports. Societe Generale restated a “hold” rating on shares of Novartis AG in a research note on Thursday, October 27th. Argus upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research note on Thursday, November 10th. Chardan Capital lowered their target price on shares of Novartis AG from $95.00 to $92.00 and set a “buy” rating for the company in a research note on Monday, October 10th. Zacks Investment Research lowered shares of Novartis AG from a “hold” rating to a “sell” rating in a research note on Wednesday, September 21st. Finally, TheStreet lowered shares of Novartis AG from a “buy” rating to a “hold” rating in a research note on Wednesday, September 28th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $88.50.
Novartis AG (NYSE:NVS) traded down 2.04% during mid-day trading on Friday, hitting $71.06. 932,880 shares of the stock traded hands. Novartis AG has a 1-year low of $69.84 and a 1-year high of $89.15. The firm has a market cap of $168.80 billion, a price-to-earnings ratio of 25.06 and a beta of 0.71. The stock has a 50-day moving average of $74.53 and a 200 day moving average of $78.57.
Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 25th. The company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.04. The business earned $12.13 billion during the quarter, compared to analyst estimates of $12.24 billion. Novartis AG had a net margin of 13.98% and a return on equity of 15.25%. The business’s revenue was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.27 earnings per share. On average, equities analysts expect that Novartis AG will post $4.72 EPS for the current year.
Large investors have recently modified their holdings of the stock. Integrated Investment Consultants LLC increased its stake in shares of Novartis AG by 6.3% in the second quarter. Integrated Investment Consultants LLC now owns 1,240 shares of the company’s stock worth $102,000 after buying an additional 74 shares during the last quarter. Whitnell & Co. raised its stake in Novartis AG by 14.6% in the second quarter. Whitnell & Co. now owns 1,410 shares of the company’s stock worth $116,000 after buying an additional 180 shares in the last quarter. Iowa State Bank purchased a new stake in Novartis AG during the second quarter worth approximately $122,000. M&R Capital Management Inc. purchased a new stake in Novartis AG during the second quarter worth approximately $122,000. Finally, WFG Advisors LP raised its stake in Novartis AG by 8.9% in the second quarter. WFG Advisors LP now owns 1,624 shares of the company’s stock worth $134,000 after buying an additional 133 shares in the last quarter. 9.80% of the stock is owned by institutional investors.
About Novartis AG
Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.
Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.